NCT04013334View on ClinicalTrials.gov

MTG201 Plus Nivolumab in Patients With Relapsed Pleural Mesothelioma

PHASE2UnknownINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

August 15, 2019

Primary Completion Date

December 31, 2022

Study Completion Date

January 1, 2023

Conditions
Malignant Pleural Mesothelioma
Interventions
DRUG

MTG201

MTG201, 3 x 10E12 vp delivered by intratumoral injection on days 1, 8, 22 and 50

DRUG

Nivolumab Injection [Opdivo]

Nivolumab 480 mg by IV infusion every 4 weeks

Trial Locations (1)

77030

Baylor College of Medicine, Houston

Sponsors

Lead Sponsor

Momotaro-Gene Inc.
All Listed Sponsors
collaborator

Baylor College of Medicine

OTHER

collaborator

Synteract, Inc.

INDUSTRY

lead

Momotaro-Gene Inc.

INDUSTRY

NCT04013334 - MTG201 Plus Nivolumab in Patients With Relapsed Pleural Mesothelioma | Biotech Hunter | Biotech Hunter